UCLA Health
S

ASCO 2021 Highlights on the Outcomes in Patients ≥ 65 Years in the ASCENT Study of Sacituzumab Govitecan in mTNBC

By UCLA Health FEATURING Sara A. Hurvitz
By UCLA Health FEATURING Sara A. Hurvitz
87 views
October 13, 2021
1 Comment
Login to view comments. Click here to Login

Related Content

AUTOPLAY
London Breast Meeting

London Breast Meeting 2024

Wed, Sep 4, 2024
12:35
Insights from 2023 SABCS

SABCS 2023 Summary: "What Is the Appropriate 1L Therapy for ER+…

Feat. S. Tolaney, H. Rugo
17:20
Insights from 2023 ESMO Annual Meeting

ESMO 2023 Summary: "Top 5 Breast Cancer Studies Including KEYNO…

Feat. P. Tarantino
14:16
Dana-Farber Cancer Institute

Year in Review: Breast Cancer

Feat. P. Tarantino
04:28
Insights from 2023 ASCO® Annual Meeting

ASCO® 2023 Insights: "ASCENT-05/OptimICE-RD (AFT-65): Adjuvant …

Feat. S. Tolaney
49:07
SABCS 2022 Conference Coverage

SABCS 2022 Expert Panel Discussion: Practice-Changing Updates

Feat. J. O'Shaughnessy, S. Tolaney, S. Hurvitz, H. Rugo
07:50
Oncology Data Advisor

ESMO 2023 Insights: "Real-World Use Patterns, Effectiveness, &a…

Feat. K. Kalinsky
22:34
Dana-Farber Cancer Institute

What's New in Breast Cancer?

Feat. S. Tolaney
17:35
Insights from 2023 SABCS

SABCS 2023 Summary: "Top 5 Studies Including KATHERINE & HE…

Feat. P. Tarantino
30:46
Insights from 2023 ESMO Annual Meeting

ESMO 2023 Panel Discussion: "Metastatic Breast Cancer"

Feat. S. Tolaney, H. Rugo
24:36
ESMO 2022 Conference Coverage

ESMO 2022 Breast Cancer Panel Discussion: Practice-Changing Updates

Feat. H. Rugo, J. O'Shaughnessy
21:37
Dana-Farber Cancer Institute

Standard Treatments for HR+/HER2- mBC in 2023

Feat. S. Sammons
12:21
Insights from 2023 SABCS

SABCS 2023 Insights: "How to Treat TNBC"

Feat. P. Sharma
03:24
ecancer

SABCS 2022 EMERALD Phase 3 Trial: Elacestrant and PFS in ER+/HER2- m…

Feat. V. Kaklamani
20:42
Total Health

2022 Updates in TNBC

Feat. I. Schlam
13:23
Insights from 2023 ESMO Annual Meeting

ESMO 2023 Summary: "A Pooled Analysis of T-DXd for HER2+ mBC Wi…

Feat. S. Hurvitz
20:16
University of Colorado Cancer Center

Updated NCCN Guidelines for HR+/HER2- mBC: Treatment Options in 1L S…

Feat. V. Borges
12:24
Stanford Medicine

HR+ mBC: CDK4/6i Progression Management

Feat. M. Dolezal
11:19
Adam Brufsky

HER2+ mBC: The Role of TDM-1

03:37
Insights from 2023 SABCS

SABCS 2023 Summary: "Is There a Role for Purely Adjuvant IO in …

Feat. S. Tolaney, H. Rugo
13:32
13th Annual Winter Breast Cancer Symposium

2023 Advances in HR+ mBC: CDK4/6i, SERDs, and ADCs

Feat. W. Gradishar